What Intrepid Labs does
Intrepid Labs, a University of Toronto spinout, built Valiant, a robotic lab platform that selects, prepares, and analyzes drug formulations through partial and fully autonomous workflows. The company says the system can deliver formulation results in days instead of the months typical of traditional trial-and-error testing, while also screening delivery formats, dosing frequencies, and patient-experience parameters. Intrepid partners with pharma companies ranging from emerging biotechs to large global manufacturers, and lists Quotient Sciences as a strategic partner. It is also developing proprietary oral and long-acting injectable delivery technologies available for licensing.
Intrepid Labs is a research tool on Falcoscan. AI-driven robotic lab platform that speeds up drug formulation development. Falcoscan rates Intrepid Labs with an Opportunity score of 78/100, a Saturation score of 14/100, and a Wrapper-risk score of 15/100. Market signal: rising. Intrepid Labs is founded in 2023, currently at Seed stage. Pricing: Paid.